These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 19826044

  • 1. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
    Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H.
    Cancer Res; 2009 Nov 01; 69(21):8386-94. PubMed ID: 19826044
    [Abstract] [Full Text] [Related]

  • 2. Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer.
    Jiang J, Huang H.
    Mol Cell Pharmacol; 2010 Jan 01; 2(1):1-5. PubMed ID: 20419056
    [Abstract] [Full Text] [Related]

  • 3. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.
    Liu P, Li S, Gan L, Kao TP, Huang H.
    Cancer Res; 2008 Dec 15; 68(24):10290-9. PubMed ID: 19074897
    [Abstract] [Full Text] [Related]

  • 4. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
    Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang KH, Wu CT, Chang C.
    J Biol Chem; 2005 Sep 30; 280(39):33558-65. PubMed ID: 16061480
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
    Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL.
    Endocr Relat Cancer; 2009 Dec 30; 16(4):1157-69. PubMed ID: 19635783
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
    Dai Y, Ngo D, Jacob J, Forman LW, Faller DV.
    Carcinogenesis; 2008 Sep 30; 29(9):1725-33. PubMed ID: 18487222
    [Abstract] [Full Text] [Related]

  • 9. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
    Mediwala SN, Sun H, Szafran AT, Hartig SM, Sonpavde G, Hayes TG, Thiagarajan P, Mancini MA, Marcelli M.
    Prostate; 2013 Feb 15; 73(3):267-77. PubMed ID: 22821817
    [Abstract] [Full Text] [Related]

  • 10. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
    Cherian MT, Wilson EM, Shapiro DJ.
    J Biol Chem; 2012 Jul 06; 287(28):23368-80. PubMed ID: 22589544
    [Abstract] [Full Text] [Related]

  • 11. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ.
    Proc Natl Acad Sci U S A; 2016 May 31; 113(22):6259-64. PubMed ID: 27185910
    [Abstract] [Full Text] [Related]

  • 12. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
    Siddique HR, Mishra SK, Karnes RJ, Saleem M.
    Clin Cancer Res; 2011 Aug 15; 17(16):5379-91. PubMed ID: 21712449
    [Abstract] [Full Text] [Related]

  • 13. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.
    Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatzis G, Janknecht R.
    Cancer Res; 2009 Oct 15; 69(20):8102-10. PubMed ID: 19789348
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells.
    Kim SH, Singh SV.
    Mol Cancer Ther; 2009 Jul 15; 8(7):1946-54. PubMed ID: 19584240
    [Abstract] [Full Text] [Related]

  • 16. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
    Ma L, Yan Y, Bai Y, Yang Y, Pan Y, Gang X, Karnes RJ, Zhang J, Lv Q, Wu Q, Huang H.
    Theranostics; 2019 Jul 15; 9(17):5020-5034. PubMed ID: 31410199
    [Abstract] [Full Text] [Related]

  • 17. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
    Steely AM, Willoughby JA, Sundar SN, Aivaliotis VI, Firestone GL.
    Anticancer Drugs; 2017 Oct 15; 28(9):1018-1031. PubMed ID: 28708672
    [Abstract] [Full Text] [Related]

  • 18. Intracrine androgen biosynthesis in renal cell carcinoma.
    Lee GT, Han CS, Kwon YS, Patel R, Modi PK, Kwon SJ, Faiena I, Patel N, Singer EA, Ahn HJ, Kim WJ, Kim IY.
    Br J Cancer; 2017 Mar 28; 116(7):937-943. PubMed ID: 28253524
    [Abstract] [Full Text] [Related]

  • 19. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T, Naito S.
    Prostate; 2013 Sep 28; 73(12):1336-44. PubMed ID: 23775496
    [Abstract] [Full Text] [Related]

  • 20. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R.
    Clin Cancer Res; 2013 Oct 15; 19(20):5613-25. PubMed ID: 23995860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.